Publications by authors named "T Yanagawa"
The linear no-threshold (LNT) model, which has been used for radiation protection purposes, was developed based on the assumption that exposure to even a small amount of radiation may cause cancer. However, although it is known in carcinogenesis that there is variation in radiation sensitivity among individuals, the LNT model does not adequately consider radiosensitive subgroups. In this paper, we represent susceptibility to contract cancer by radiation exposure by means of the threshold of a dose-response function, introduce an assumption that the thresholds are random to represent the variation of the radiosensitivity among individuals in a susceptible subgroup.
View Article and Find Full Text PDFArticle Synopsis
- There is limited research on how effective and safe the tyrosine kinase inhibitors osimertinib (OSI) and gefitinib (GEF) are for treating EGFR mutation-positive non-small cell lung cancer (NSCLC) in patients with low performance status (PS).
- A study reviewed data from 113 patients, comparing the safety and efficacy of OSI and GEF, showing overall response rates of approximately 69% for GEF and 66% for OSI, with median progression-free survival being 6.9 months for GEF and 9.2 months for OSI.
- Results indicated that OSI offered better overall survival (20.9 months) compared to GEF (13.0 months
Background: Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that inhibits the degradation of endogenous natriuretic peptides. Therefore, ARNIs may increase the efficacy of human atrial natriuretic peptide (hANP), a drug for acute heart failure, by mediating its pharmacological mechanism. This study was aimed at evaluating the effects of ARNIs on the pharmacological effects of hANP by using surrogate marker, such as urinary output, in patients with heart failure.
View Article and Find Full Text PDF